Novartis
NVS
1,132 hedge funds and large institutions have $20.4B invested in Novartis in 2020 Q1 according to their latest regulatory filings, with 87 funds opening new positions, 422 increasing their positions, 457 reducing their positions, and 110 closing their positions.
47% more call options, than puts
Call options by funds: $158M | Put options by funds: $107M
30% more funds holding in top 10
Funds holding in top 10: 23 → 30 (+7)
0.45% less ownership
Funds ownership: 11.52% → 11.07% (-0.45%)
8% less repeat investments, than reductions
Existing positions increased: 422 | Existing positions reduced: 457
3% less funds holding
Funds holding: 1,173 → 1,132 (-41)
16% less capital invested
Capital invested by funds: $24.4B → $20.4B (-$3.97B)
21% less first-time investments, than exits
New positions opened: 87 | Existing positions closed: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$386M |
| 2 |
Renaissance Technologies
New York
|
+$169M |
| 3 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
+$150M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$139M |
| 5 |
FAM
Fred Alger Management
New York
|
+$92.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSIA
Charles Schwab Investment Advisory
San Francisco,
California
|
-$417M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$416M |
| 3 |
BlackRock
New York
|
-$305M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$260M |
| 5 |
Jennison Associates
New York
|
-$234M |
NVS Hedge Fund Activity: Q1 2020 in Review
1,132 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2020, worth a combined $20.4B — down 16% from $24.4B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of NVS and 87 opened new positions — a net loss of 23 holders — while 457 trimmed existing stakes and 422 added.
The largest buyer was Charles Schwab, adding an estimated $386M. The largest seller was Charles Schwab Investment Advisory, exiting entirely with an estimated $417M sold.
- 1,132 institutional investors held Novartis (NVS) as of Q1 2020, down from 1,173 in Q4 2019.
- Funds reported $20.4B of Novartis stock for Q1 2020, down 16% quarter-over-quarter.
- 87 funds opened new Novartis positions in Q1 2020 and 110 closed out, a net change of -23 holders.
- The largest Novartis buyer in Q1 2020 was Charles Schwab, an estimated $386M added.
- The largest Novartis seller in Q1 2020 was Charles Schwab Investment Advisory, an estimated $417M sold.
Based on aggregated 13F filings for Q1 2020.